FDA To Act On COX-2 Committee Input Within "Next Few Weeks"
This article was originally published in The Pink Sheet Daily
Executive Summary
In remarks to the Arthritis Drugs/Drug Safety & Risk Management advisory committee meeting, CDER Acting Director Galson says the agency will take "rapid" action on the panel's recommendations.